Inflammation in Chronic Hepatic Diseases and Possible Approaches to the Treatment

V.V. Chernyavsky, V.V. Chernyavsky, A.K. Sizenko, L.S. Gvozdetskaya

Abstract


Inflammation reactions are the central component of liver regeneration after injury of various etiologies. The realization of these reactions involves a large number of pro-inflammatory cytokines: interferons, interleukins, tumor necrosis factors, transforming growth factors, colony stimulating factors, and chemokines. Thus, the study of different ways to influence the specific mediators of inflammation and inflammatory process in general today is a promising direction in developing strategies for the management of patients with inflammatory diseases of the liver. There remains topical the question of the appropriateness of application in this category of patients of various kinds of pathogenetic therapy agents, traditionally called hepatoprotectors. This article deals with a detailed analysis of the mechanisms of chronic inflammation in hepatitis of various etiologies, some aspects of the diagnosis of above diseases and studying the efficacy of pathogenic anti-inflammatory therapy with the definition of its place in the treatment of such pathology.


Keywords


chronic hepatic diseases, diagnosis; 13C methacetin breath test; treatment; glycyrrhizic acid

References


Дударь Л.В., Чернявский В.В., Михнева Н.Н. Коррекция антитоксической функции печени в амбулаторных условиях у пациентов с хроническими диффузными заболеваниями печени // Сучасна гастроентерологія. — 2009. — № 4 (48). — С. 66-68.

Bostan N., Mahmood T. An overview about hepatitis C: a devastating virus // Crit. Rev. Microbiol. — 2010. — № 36 (2). — Р. 91-133.

Dienstag J.L. Hepatitis B virus infection // N. Engl. J. Med. — 2008. — № 359 (14). — Р. 1486-500.

Wedemeyer H. Manns Epidemiology MP pathogenesis and management of hepatitis D: update and challenges ahead // Nature Rev. Gastroenterol. Hepatol. — 2010. — № 7 (1). — Р. 31-40.

Krawitt E.L. Autoimmune hepatitis // N. Engl. J. Med. — 2006. — 354 (1). — 54-66.

Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis // N. Engl. J. Med. — 2005. — 353 (12). — 1261-73.

Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis // N. Engl. J. Med. — 2009. — 360 (26). — 2758-69.

Iser D., Ryan M. Fatty liver disease: a practical guide for GPs // Aust. Fam. Physician. — 2013. — 42 (7). — 444-7.

Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench // Nature reviews. Gastroenterology & hepatology. — 2011.

Riehle K.J., Dan Y.Y., Campbell J.S., Fausto N. New concepts in liver regeneration // J. Gastroenterol. Hepatol. — 2011. — 26 (Suppl. 1). — 203-212.

Friedmann S., Dantes A., Amsterdam A. Ovarian transcriptomes as a tool for a global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells // Endocrine. — 2005. — 26 (3). — 259-65.

Cavazza A., Caballería L., Floreani A. et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers // Hepatology. — 2009. — 50 (4). — 1162-1168.

Demaria S., Pikarsky E., Karin M. et al. Cancer and inflammation: promise for biologic therapy // J. Immunother. — 2010. — 33 (4). — 335-51.

Montecucco F., Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? // Endocr. Metab. Immune Disord. Drug Targets. — 2008. — 8. — 301-307.

Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance // J. Clin. Invest. — 1995. — 95. — 2409-2415.

Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss // J. Clin. Endocrinol. Metab. — 1998. — 83. — 2907-2910.

Lesmana C.R., Hasan I., Budihusodo U., Gani R.A., Krisnuhoni E., Akbar N., Lesmana L.A. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis // J. Dig. Dis. — 2009. — 10. — 201-206.

Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology // Cell. — 2001. — 104. — 487-501.

Gores G.J., Kaufmann S.H. Is TRAIL hepatotoxic? // Hepatology. — 2001. — 34. — 3-6.

Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms // Annu Rev. Immunol. — 1999. — 17. — 331-367.

Kountouras J., Zavos C., Chatzopoulos D. Apoptosis in hepatitis C // J. Viral. Hepat. — 2003. — 10. — 335-342.

Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis // Front Biosci. — 2002. — 7. — d793-d807.

Schnabl B., Kweon Y.O., Frederick J.P., Wang X.F., Rippe R.A., Brenner D.A. The role of Smad3 in mediating mouse hepatic stellate cell activation // Hepatology. — 2001. — 34. — 89-100.

Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A.B., Sporn M.B., Thorgeirsson S.S. Hepatic expression of mature transforming growth factor beta1 in transgenic mice results in multiple tissue lesions // Proc. Natl. Acad. Sci. USA. — 1995. — 92. — 2572-2576.

Kanzler S., Lohse A.W., Keil A., Henninger J., Dienes H.P., Schirmacher P., Rose-John S., zum Buschenfelde K.H., Blessing M. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis // Am. J. Physiol. — 1999. — 276. — G1059-G1068.

Schnur J., Olah J., Szepesi A., Nagy P., Thorgeirsson S.S. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice // Eur. J. Gastroenterol. Hepatol. — 2004. — 16. — 127-133.

Pinzani M. PDGF and signal transduction in hepatic stellate cells // Front Biosci. — 2002. — 7. — d1720-d1726.

Beljaars L., Meijer D.K., Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis // Front Biosci. — 2002. — 7. — e214-e222.

Beljaars L., Weert B., Geerts A., Meijer D.K., Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue // Biochem. Pharmacol. — 2003. — 66. — 1307-1317.

Wu J., Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis // J. Gastroenterol. — 2000. — 35. — 665-672.

Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., Qian T., Schoonhoven R., Hagedorn C.H., Lemasters J.J., Brenner D.A. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis // J. Clin. Invest. — 2003. — 112. — 1383-1394.

Nguyen W.D., Kim D.H., Alam H.B., Provido H.S., Kirkpatrick J.R. Polyethylene glycol-superoxide dismutase inhibits lipid peroxidation in hepatic ischemia/reperfusion injury // Crit. Care. — 1999. — 3. — 127-130.

Ferret P.J., Hammoud R., Tulliez M., Tran A., Trebeden H., Jaffray P., Malassagne B., Calmus Y., Weill B., Batteux F. Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse // Hepatology. — 2001. — 33. — 1173-1180.

Tanahashi T., Mune T., Morita H. Glycyrrhizic acid supresses type 2 11-β-hydroxysteroid dehydrogenase expresosion in vivo // J. Steroid Biochem. Mol. Biol. — 2002. — 80. — 441-447.

Толстиков Г.А., Балтина Л.А., Шульц Э.Э., Покровский А.Г. Глицирризиновая кислота // Биоорганическая химия. — 1997. — 23. — 691-709.

Suzuki H., Ohta Y., Takino T., Fujisawa K., Hirayama C. The therapeutic effects of Stronger Neo Minophagen C for chronic hepatitis // Igaku no Ayumi. — 1977. — 102. — 562-8.

Miyake K., Tango T., Ota Y. et al. Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis // J. Gastroenterol. Hepatol. — 2002. — 17 (11). — 1198-204.

Hino K., Miyakawa H., Kondo T. et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis // Ed. by Shikata T., Porcell R.H., Uchida T. Viral hepatitis C, D and E. — Amsterdam: Excerpta Medica, 1987. — 295-303.

Karl-Josef Gundermann, Ann Kuenker, Erwin Kuntz, Marek DroŸdzik. Activity of essential phospholipids (EPL) from soybean in liver diseases // Pharmacol. — 2011. — 63 (3). —

-59.

Маев И.В., Вьючнова Е.С., Бабина С.М. Применение фосфоглива в лечении больных неалкогольным стеатогепатитом // Российские медицинские вести. — 2009. — 14, 4. — 28-36.




DOI: https://doi.org/10.22141/2308-2097.1 (51).2014.81927

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru